Aptose, CrystalGenomics in deal for multi-kinase inhibitor

CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside of China and Korea. The compound is a small molecule inhibitor of Bruton's tyrosine kinase (Btk), FMS-like tyrosine kinase 3 ( FLT3; CD135) and Aurora kinases.

Aptose said it expects to begin IND-enabling studies of CG026806 "immediately." If it exercises the option, it could begin a Phase I study by mid-2017 to treat hematologic malignancies. ...